Grant: Engage Plus Grants Program
University of British Columbia
$12,500.00
Research and use of high-throughput robotic screens to identify fucoidanases and sulfatases from marine environments
EF 2016-17
Résumé
Fucoidan is a polysaccharide found in seaweed that has been found, by ARC Medical Devices Inc., to be very effective in reducing adhesion developments in the abdominal cavities of animals after surgery. The success of this product in veterinary use has prompted a desire to develop the product for use in humans. Currently ARC purchases the fucoidan, but the material obtained is of heterogeneous composition. In order to move the product into the human market, they need to develop means to improve homogeneity and purity, and to lower the average molecular weight. Two routes are possible: modifying and purifying the commercial fucoidan, or enzymatically synthesising custom fucoidan from pure simple starting materials. The most practical way towards both ends is to first find enzymes that can degrade fucoidan, and use these to generate material of the desired size, then purify this lower molecular weight material. The other would be to engineer these degradative enzymes into synthetic enzymes and use these to assemble fucoidan of the desired properties. This is however challenging as fucoidanases are elusive enzymes. We have now developed high-throughput screens that allow us to find organisms producing fucoidan-degrading enzymes, and have grown up libraries of marine bacteria. We shall screen both libraries of marine bacteria and fragments of genes from marine sources, some of which may well use seaweed as a food source, to look for fucoidanase activity. We shall then identify the responsible genes and from them produce the enzymes to test whether they can carry out the desired task. Successful completion of the project will lead to a process to produce a novel, first in class medical device for the reduction of post-surgical adhesions in humans, which in turn will reduce pain, suffering, infertility and mortality in Canadian patients following common surgical procedures; reduce Canadian hospital stays, hospital re-admissions, and re-operations, which in turn will reduce healthcare costs for Canadian governments and taxpayers; and create scientific, manufacturing and sales jobs within Canada, and export of a high margin product.
Programme
Engage Plus Grants Program
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
495076-2016
Name nom
Withers, Stephen
Department département
Chemistry
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
12500
Program id
EGP2
Program name en
Engage Plus Grants Program
Program name fr
Programme de subvention d'engagement partenarial Plus
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
5406
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Carbohydrates
Research subject fr
Glucides
Partie
1
Nb partie
1
Application title
Research and use of high-throughput robotic screens to identify fucoidanases and sulfatases from marine environments
Keyword
NSERC
Application summary
Fucoidan is a polysaccharide found in seaweed that has been found, by ARC Medical Devices Inc., to be very effective in reducing adhesion developments in the abdominal cavities of animals after surgery. The success of this product in veterinary use has prompted a desire to develop the product for use in humans. Currently ARC purchases the fucoidan, but the material obtained is of heterogeneous composition. In order to move the product into the human market, they need to develop means to improve homogeneity and purity, and to lower the average molecular weight. Two routes are possible: modifying and purifying the commercial fucoidan, or enzymatically synthesising custom fucoidan from pure simple starting materials. The most practical way towards both ends is to first find enzymes that can degrade fucoidan, and use these to generate material of the desired size, then purify this lower molecular weight material. The other would be to engineer these degradative enzymes into synthetic enzymes and use these to assemble fucoidan of the desired properties. This is however challenging as fucoidanases are elusive enzymes. We have now developed high-throughput screens that allow us to find organisms producing fucoidan-degrading enzymes, and have grown up libraries of marine bacteria. We shall screen both libraries of marine bacteria and fragments of genes from marine sources, some of which may well use seaweed as a food source, to look for fucoidanase activity. We shall then identify the responsible genes and from them produce the enzymes to test whether they can carry out the desired task. Successful completion of the project will lead to a process to produce a novel, first in class medical device for the reduction of post-surgical adhesions in humans, which in turn will reduce pain, suffering, infertility and mortality in Canadian patients following common surgical procedures; reduce Canadian hospital stays, hospital re-admissions, and re-operations, which in turn will reduce healthcare costs for Canadian governments and taxpayers; and create scientific, manufacturing and sales jobs within Canada, and export of a high margin product.